Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 36-45

  Sargentini Maier, Maria Laura ^a   Espié, Pascal ^a   Coquette, Alain ^b   Stockis, Armel ^a  

^a UCB PHARMA   (Belgium)

^b SGS Medisearch International NV   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 [ 2 OXO 4 (2 OXOPROPYL)PYRROLIDIN 1 YL]BUTANAMIDE; 2 [2 OXO 4 (2 HYDROXY PROPYL)PYRROLIDIN 1 YL]BUTANAMIDE; 2 [2 OXO 4 (2 HYDROXYPROPYL)PYRROLIDIN 1 YL]BUTANAMIDE; 2 [2 OXO 4 PROPYLPYRROLIDIN 1 YL]BUTANOIC ACID; AMIDE; BRIVARACETAM; CARBON 14; CYTOCHROME P450; DRUG METABOLITE; GLUCURONIC ACID; HYDROXYACID; LIGAND; PROPANE; TAURINE; UNCLASSIFIED DRUG; 2 (2 OXO 4 PROPYLPYRROLIDIN 1 YL)BUTANAMIDE; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE; ANTICONVULSIVE AGENT; CARBON; MEMBRANE PROTEIN; NERVE PROTEIN; SV2A PROTEIN, HUMAN;

ADULT; ANTICONVULSANT ACTIVITY; ARTICLE; BIOTRANSFORMATION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG METABOLISM; EXPIRED AIR; FECES ANALYSIS; FIRST PASS EFFECT; HUMAN; HUMAN TISSUE; HYDROLYSIS; HYDROXYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RADIOACTIVITY; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION; BLOOD; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION; URINE;

ADMINISTRATION, ORAL; ANTICONVULSANTS; CARBON RADIOISOTOPES; HUMANS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; METABOLIC CLEARANCE RATE; NERVE TISSUE PROTEINS; PYRROLIDINONES; TISSUE DISTRIBUTION;

EID: 37549020621     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017129     Document Type: Article

References (13)

1. ICRP Publication 60 (1991) 1990 Recommendations of the International Commission on Radiological Protection, Pergamon Press, Oxford, UK.
2. ICRP Publication 62 (1993) Radiological Protection in Biomedical Research, Pergamon Press, Oxford, UK.
3. Kasteleijn-Nolst Trenité DGA, Genton P, Parain D, Masnou P, Steinhoff BJ, Jacobs T, Pigeolet E, Stockis A, and Hirsch E (2007) Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 69:1027-1034.
4. Kenda BM, Matagne AC, Talaga PE, Pasau PM, Differding E, Lallemand BI, Frycia AM, Moureau FG, Klitgaard HV, Gillard MR, et al. (2004) Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 47:530-549.
5. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, and Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861-9866.
6. Matagne A, Kenda B, Michel P, and Klitgaard H (2003a) UCB 34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models of chronic epilepsy in vivo. Epilepsia 44 (Suppl 9):260-261.
7. Matagne A, Kenda B, Michel P, and Klitgaard H (2003b) UCB 34714, a new pyrrolidone derivative, suppresses seizures epileptogenesis in animal models of chronic epilepsy in vivo. Epilepsia 44 (Suppl 8):53-54.
8. Rigo JM, Nguyen L, Hans G, Belachew S, Moonen G, Matagne A, and Klitgaard H (2004) UCB 34714: effect on inhibitory and excitatory neurotransmission. Epilepsia 45 (Suppl 3):56.
9. Rolan P, Pigeolet E, and Stockis A (2004) UCB 34714: single and multiple rising dose safety, tolerability, and pharmacokinetics in healthy subjects. Epilepsia 45 (Suppl 7):314-315.
10. Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, and Stockis A (2007) Brivaracetam safety, tolerability, pharmacokinetics and CNS pharmacodynamic effects after 10 to 1400 mg single rising oral doses in healthy males. Br J Clin Pharmacol 63:680-688.
11. Strolin Benedetti M, Whomsley R, Nicolas JM, Young C, and Baltes E (2003) Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy subjects. Eur J Clin Pharmacol 59:621-630.
12. Whomsley R, Brochot A, Dell'Aiera S, Delepine X, and Espié P (2007) Identification of the cytochrome P450 isoforms responsible for the hydroxylation of brivaracetam (Abstract). AAPS Journal 9(Suppl 2):T3408.
13. + currents in rat cortical neurons in culture. Epilepsia 45 (Suppl 7):146.